

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 February 2001 (01.02.2001)


PCT

(10) International Publication Number
WO 01/07572 A2

- (51) International Patent Classification⁷: C12N 5/10, 15/79, 15/90 // 9/22
- (21) International Application Number: PCT/US00/19983
- (22) International Filing Date: 21 July 2000 (21.07.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/145,469 23 July 1999 (23.07.1999) US
- (71) Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; Office Of Technology Transfer, 1111 Franklin Street, 12th floor, Oakland, CA 94607-5200 (US). THE UNITED STATES OF AMERICA as represented by the SECRETARY OF AGRICULTURE [US/US]; 1400 Independence Avenue S.W., Washington, DC 20250 (US).
- (72) Inventors: OW, David, W.; 127 Brenner Street, Hercules, CA 94547-3749 (US). CALENDAR, Richard; 940 Euclid Street, Berkeley, CA 94708-1436 (US). THOMASON, Lynn; 1061 H. Monroe Street #7, Albany, CA 94706-2282 (US).
- (74) Agents: SMITH, Timothy, L. et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th floor, San Francisco, CA 94111-3834 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

[Continued on next page]

(54) Title: DNA RECOMBINATION IN EUKARYOTIC CELLS BY THE BACTERIOPHAGE PHIC31 RECOMBINATION SYSTEM



(57) Abstract: This invention provides methods for obtaining specific and stable integration of nucleic acids into eukaryotic cells. The invention makes use of site-specific recombination systems that use prokaryotic recombinase polypeptides, such as the Φ C31 integrase, that can mediate recombination between the recombination sites, but not between hybrid recombination sites that are formed upon the recombination. Thus, the recombination is irreversible in the absence of additional factors. Eukaryotic cells that contain the recombinase polypeptides, or genes that encode the recombinases, are also provided.

WO 01/07572 A2



IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *Without international search report and to be republished upon receipt of that report.*

DNA RECOMBINATION IN EUKARYOTIC CELLS BY THE BACTERIOPHAGE PHIC31 RECOMBINATION SYSTEM

5

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

This invention was made with government support under Grant No. 5335-21000-009-06S, awarded by the United States Department of Agriculture, Agricultural Research Service. The Government has certain rights in the invention.

10

CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of US Provisional Application No. 60/145,469, filed July 23, 1999, which application is incorporated herein by reference.

BACKGROUND OF THE INVENTION

Field of the Invention

15

This invention pertains to the field of methods for obtaining specific and stable integration of nucleic acids into chromosomes of eukaryotes. The invention makes use of site-specific recombination systems that use prokaryotic recombinase polypeptides, such as the Φ C31 integrase.

Background

20

Genetic transformation of eukaryotes often suffers from significant shortcomings. For example, it is often difficult to reproducibly obtain integration of a transgene at a particular locus of interest. Homologous recombination generally occurs only at a very low frequency. To overcome this problem, site-specific recombination systems have been employed. These methods involve the use of site-specific recombination systems that can operate in higher eucaryotic cells.

25

Many bacteriophage and integrative plasmids encode site-specific recombination systems that enable the stable incorporation of their genome into those of

their hosts. In these systems, the minimal requirements for the recombination reaction are a recombinase enzyme, or integrase, which catalyzes the recombination event, and two recombination sites (Sadowski (1986) *J. Bacteriol.* 165: 341-347; Sadowski (1993) *FASEB J.* 7: 760-767). For phage integration systems, these are referred to as attachment (*att*) sites, with an *attP* element from phage DNA and the *attB* element encoded by the bacterial genome. The two attachment sites can share as little sequence identity as a few base pairs. The recombinase protein binds to both *att* sites and catalyzes a conservative and reciprocal exchange of DNA strands that result in integration of the circular phage or plasmid DNA into host DNA. Additional phage or host factors, such as the DNA bending protein IHF, integration host factor, may be required for an efficient reaction (Friedman (1988) *Cell* 55:545-554; Finkel & Johnson (1992) *Mol. Microbiol.* 6: 3257-3265). The reverse excision reaction sometimes requires an additional phage factor, such as the *xis* gene product of phage λ (Weisberg & Landy (1983) "Site-specific recombination in phage lambda." In *Lambda II*, eds. Hendrix *et al.* (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY) pp.211-250; Landy (1989) *Ann. Rev. Biochem.* 58: 913-949).

The recombinases have been categorized into two groups, the λ integrase (Argos *et al.* (1986) *EMBO J.* 5: 433-44; Voznyanov *et al.* (1999) *Nucl. Acids Res.* 27: 930-941) and the resolvase/invertase (Hatfull & Grindley (1988) "Resolvases and DNA-invertases: a family of enzymes active in site-specific recombination" In *Genetic Recombination*, eds. Kucherlipati, R., & Smith, G. R. (Am. Soc. Microbiol., Washington DC), pp. 357-396) families. These vary in the structure of the integrase enzymes and the molecular details of their mode of catalysis (Stark *et al.* (1992) *Trends Genetics* 8: 432-439). The temperate *Streptomyces* phage Φ C31 encodes a 68 kD recombinase of the latter class. The efficacy of the Φ C31 integrase enzyme in recombining its cognate attachment sites was recently demonstrated *in vitro* and *in vivo* in *recA* mutant *Escherichia coli* (Thorpe & Smith (1998) *Proc. Nat'l. Acad. Sci. USA* 95: 5505-5510). The Φ C31 integration reaction is simple in that it does not require a host factor and appears irreversible, most likely because an additional phage protein is required for excision. The phage and bacterial *att* sites share only three base pairs of homology at the point of cross-over. This homology is flanked by inverted repeats, presumably binding sites for the integrase protein. The minimal known functional size for both *attB* and *attP* is ~50 bp.

The Cre-lox system of bacteriophage P1, and the FLP-FRT system of *Saccharomyces cerevisiae* have been widely used for transgene and chromosome engineering in animals and plants (reviewed by Sauer (1994) *Curr. Opin. Biotechnol.* 5: 521-527; Ow (1996) *Curr. Opin. Biotechnol.* 7: 181-186). Other systems that operate in animal or plant cells include the following: 1) the R-RS system from *Zygosaccharomyces rouxii* (Onouchi *et al.* (1995) *Mol. Gen. Genet.* 247: 653-660), 2) the Gin-gix system from bacteriophage Mu (Maeser & Kahmann (1991) *Mol. Gen. Genet.* 230: 170-176) and, 3) the β recombinase-six system from bacterial plasmid pSM19035 (Diaz *et al.* (1999) *J. Biol. Chem.* 274: 6634-6640). By using the site-specific recombinases, one can obtain a greater frequency of integration.

However, these five systems suffer from a significant shortcoming. Each of these systems have in common the property that a single polypeptide recombinase catalyzes the recombination between two sites of identical or nearly identical sequences. The product-sites generated by recombination are themselves substrates for subsequent recombination. Consequently, recombination reactions are readily reversible. Since the kinetics of intramolecular interactions are favored over intermolecular interactions, these recombination systems are efficient for deleting rather than integrating DNA. Thus, a need exists for methods and systems for obtaining stable site-specific integration of transgenes. The present invention fulfills this and other needs.

SUMMARY OF THE INVENTION

The present invention provides methods for obtaining stable, site-specific recombination in a eukaryotic cell. Unlike previously known methods for site-specific recombination, the recombinants obtained using the methods of the invention are stable. The recombination reaction is not reversible.

The methods involve providing a eukaryotic cell that comprises a first recombination site and a second recombination site, which second recombination site can serve as a substrate for recombination with the first recombination site. The first and the second recombination sites are contacted with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination sites, thereby forming one or two hybrid recombination sites. Significantly, the recombinase polypeptide is one that can

mediate site-specific recombination between the first and second recombination sites, but cannot mediate recombination between the two hybrid recombination sites in the absence of an additional phage-produced factor that is not present in the eukaryotic cell. Either or both of the recombination sites can be present in a chromosome of the eukaryotic cell. In some
5 embodiments, one of the recombination sites is present in the chromosome and the other is included within a nucleic acid that is to be integrated into the chromosome.

 The invention also provides eukaryotic cells that contain a prokaryotic recombinase polypeptide or a nucleic acid that encodes a prokaryotic recombinase. In these
10 embodiments, the recombinase is one that can mediate site-specific recombination between a first recombination site and a second recombination site that can serve as a substrate for recombination with the first recombination site, but in the absence of an additional factor that is not present in the eukaryotic cell cannot mediate recombination between two hybrid recombination sites that are formed upon recombination between the first recombination site and the second recombination site. In presently preferred embodiments, the cells of the
15 invention include a nucleic acid that has a coding sequence for a recombinase polypeptide. The recombinase coding sequence is preferably operably linked to a promoter that mediates expression of the recombinase-encoding polynucleotide in the eukaryotic cell. The eukaryotic cells of the invention can be an animal cell, a plant cell, a yeast cell or a fungal cell, for example.

20 In additional embodiments, the invention provides methods for obtaining a eukaryotic cell having a stably integrated transgene. These methods involve introducing a nucleic acid into a eukaryotic cell that comprises a first recombination site, wherein the nucleic acid comprises the transgene of interest and a second recombination site which can serve as a substrate for recombination with the first recombination site. The first and second
25 recombination sites are contacted with a prokaryotic recombinase polypeptide. The recombinase polypeptide catalyzes recombination between the first and second recombination sites, resulting in integration of the nucleic acid at the first recombination site, thereby forming a hybrid recombination site at each end of the nucleic acid. Again, the recombinase polypeptide is one that can mediate site-specific recombination between the
30 first and second recombination sites, but cannot mediate recombination between two hybrid

recombination sites in the absence of an additional factor that is not present in the eukaryotic cell.

Additional embodiments of the invention provide nucleic acids that include a polynucleotide sequence that encodes a bacterial recombinase polypeptide operably linked to a promoter that functions in a eukaryotic cell. The recombinase polypeptides encoded by these nucleic acids of the invention cannot mediate recombination between two hybrid recombination sites that are formed upon recombination between a first recombination site and a second recombination site in the absence of a bacteriophage factor that is not present in the eukaryotic cells. In some embodiments, the nucleic acids further include at least one recombination site that is recognized by the recombinase polypeptide.

Also provided by the invention are eukaryotic cells that include a polynucleotide that has one or more bacteriophage Φ C31 recombination sites, or recombination sites for other recombinases that cannot mediate recombination between two hybrid recombination sites that are formed upon recombination between a first recombination site and a second recombination site in the absence of a bacteriophage factor that is not present in the eukaryotic cells.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a schematic (not to scale) representation of the chromosome structure at the *S. pombe leu1* locus. Homologous insertion of pLT44 into the chromosome (Figure 1A) places a Φ C31 *attP* target between *leu1* alleles as shown in Figure 1B. pLT43 promoted site-specific integration of pLT45 into the chromosomal *attP* target leads to the structure shown in Figure 1C. Arrowheads indicate PCR primers corresponding to the T7 promoter (T7), T3 promoter (T3) and *ura4*⁺ coding region (U4). Predicted sizes of *Xba*I (X) cleavage products are shown.

Figure 2 shows a schematic of an experiment which demonstrated that Φ C31 integrase catalyzes site-specific integration of a transgene encoding green fluorescent protein (GFP) in CHO cells.

Figure 3 shows a schematic diagram of an experiment which demonstrated that Φ C31 catalyzes specific recombination at an *attB* site to insert a hygromycin phosphotransferase gene downstream of a chromosomally located promoter. Successful

integration produces a *Pc-attL-hpt* linkage and a hygromycin resistance phenotype. The effect of different lengths of *attP* and *attB* sites were analyzed using the plasmids indicated.

Figure 4 shows a schematic diagram of an experiment which demonstrates that Φ C31 integrase catalyzes the excision of a DNA flanked by *attB* and *attP* sites from the tobacco genome.

Figure 5 shows a schematic diagram of an experiment in which Φ C31 integrase was shown to catalyze integration of a transgene into the tobacco genome.

DETAILED DESCRIPTION

Definitions

10 An "exogenous DNA segment", "heterologous polynucleotide" a "transgene" or a "heterologous nucleic acid", as used herein, is one that originates from a source foreign to the particular host cell, or, if from the same source, is modified from its original form. Thus, a heterologous gene in a host cell includes a gene that is endogenous to the particular host cell, but has been modified. Thus, the terms refer to a DNA segment which is foreign or
15 heterologous to the cell, or homologous to the cell but in a position within the host cell nucleic acid in which the element is not ordinarily found. Exogenous DNA segments are expressed to yield exogenous polypeptides.

The term "gene" is used broadly to refer to any segment of DNA associated with a biological function. Thus, genes include coding sequences and/or the regulatory
20 sequences required for their expression. Genes can also include nonexpressed DNA segments that, for example, form recognition sequences for other proteins. Genes can be obtained from a variety of sources, including cloning from a source of interest or synthesizing from known or predicted sequence information, and may include sequences designed to have desired parameters.

25 The term "isolated", when applied to a nucleic acid or protein, denotes that the nucleic acid or protein is essentially free of other cellular components with which it is associated in the natural state. It is preferably in a homogeneous state although it can be in either a dry or aqueous solution. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high
30 performance liquid chromatography. A protein which is the predominant species present in a

preparation is substantially purified. In particular, an isolated gene is separated from open reading frames which flank the gene and encode a protein other than the gene of interest. The term "purified" denotes that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. Particularly, it means that the nucleic acid or protein is at least
5 about 50% pure, more preferably at least about 85% pure, and most preferably at least about 99% pure.

The term "naturally-occurring" is used to describe an object that can be found in nature as distinct from being artificially produced by man. For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be
10 isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturally-occurring.

The term "nucleic acid" or "polynucleotide" refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form. Unless specifically limited, the term encompasses nucleic acids containing known analogues of
15 natural nucleotides which have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g. degenerate codon substitutions) and complementary sequences and as well as the sequence explicitly indicated. Specifically, degenerate codon
20 substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer *et al.* (1991) *Nucleic Acid Res.* 19: 5081; Ohtsuka *et al.* (1985) *J. Biol. Chem.* 260: 2605-2608; Cassol *et al.* (1992) ; Rossolini *et al.* (1994) *Mol. Cell. Probes* 8: 91-98). The term nucleic acid is used interchangeably with gene, cDNA, and mRNA encoded by a gene.

25 "Nucleic acid derived from a gene" refers to a nucleic acid for whose synthesis a gene, or a subsequence thereof (e.g., coding region), has ultimately served as a template. Thus, an mRNA, a cDNA reverse transcribed from an mRNA, an RNA transcribed from that cDNA, a DNA amplified from the cDNA, an RNA transcribed from the amplified DNA, *etc.*, are all derived from the gene and detection of such derived products is indicative
30 of the presence and/or abundance of the original.

A DNA segment is "operably linked" when placed into a functional relationship with another DNA segment. For example, DNA for a signal sequence is operably linked to DNA encoding a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to
5 a coding sequence if it stimulates the transcription of the sequence. Generally, DNA sequences that are operably linked are contiguous, and in the case of a signal sequence both contiguous and in reading phase. However, enhancers, for example, need not be contiguous with the coding sequences whose transcription they control. Linking is accomplished by ligation at convenient restriction sites or at adapters or linkers inserted in lieu thereof.

10 "Plant" includes whole plants, plant organs (*e.g.*, leaves, stems, roots, etc.), seeds and plant cells and progeny of same. The class of plants that can be used in the methods of the invention is generally as broad as the class of higher plants amenable to transformation techniques, including both monocotyledonous and dicotyledonous plants.

"Promoter" refers to a region of DNA involved in binding the RNA
15 polymerase to initiate transcription. An "inducible promoter" refers to a promoter that directs expression of a gene where the level of expression is alterable by environmental or developmental factors such as, for example, temperature, pH, transcription factors and chemicals.

The term "recombinant" when used with reference to a cell indicates that the
20 cell replicates a heterologous nucleic acid, or expresses a peptide or protein encoded by a heterologous nucleic acid. Recombinant cells can contain polynucleotides that are not found within the native (non-recombinant) form of the cell. Recombinant cells can also contain polynucleotides found in the native form of the cell wherein the polynucleotides are modified and re-introduced into the cell by artificial means. The term also encompasses cells
25 that contain a nucleic acid endogenous to the cell that has been modified without removing the nucleic acid from the cell; such modifications include those obtained by gene replacement, site-specific mutation, and related techniques.

A "recombinant expression cassette" or simply an "expression cassette" is a
nucleic acid construct, generated recombinantly or synthetically, with nucleic acid elements
30 that are capable of effecting expression of a structural gene in hosts compatible with such sequences. Expression cassettes include at least promoters and optionally, transcription

termination signals. Typically, the recombinant expression cassette includes a nucleic acid to be transcribed (*e.g.*, a nucleic acid encoding a desired polypeptide), and a promoter. Additional factors necessary or helpful in effecting expression may also be used as described herein. For example, an expression cassette can also include nucleotide sequences that
5 encode a signal sequence that directs secretion of an expressed protein from the host cell. Transcription termination signals, enhancers, and other nucleic acid sequences that influence gene expression, can also be included in an expression cassette.

“Recombinase” refers to an enzyme that catalyzes recombination between two or more recombination sites. Recombinases useful in the present invention catalyze
10 recombination at specific recombination sites which are specific polynucleotide sequences that are recognized by a particular recombinase. The term “integrase” refers to a type of recombinase.

“Transformation rate” refers to the percent of cells that successfully incorporate a heterologous polynucleotide into its genome and survive.

15 The term “transgenic” refers to a cell that includes a specific modification that was introduced into the cell, or into an ancestor of the cell. Such modifications can include one or more point mutations, deletions, insertions, or combinations thereof. When referring to an animal, the term “transgenic” means that the animal includes cells that are transgenic. An animal that is composed of both transgenic and non-transgenic cells is referred to herein
20 as a “chimeric” animal.

The term “vector” refers to a composition for transferring a nucleic acid (or nucleic acids) to a host cell. A vector comprises a nucleic acid encoding the nucleic acid to be transferred, and optionally comprises a viral capsid or other materials for facilitating entry of the nucleic acid into the host cell and/or replication of the vector in the host cell (*e.g.*,
25 reverse transcriptase or other enzymes which are packaged within the capsid, or as part of the capsid).

“Recombination sites” are specific polynucleotide sequences that are recognized by the recombinase enzymes described herein. Typically, two different sites are involved (termed “complementary sites”), one present in the target nucleic acid (*e.g.*, a
30 chromosome or episome of a eukaryote) and another on the nucleic acid that is to be integrated at the target recombination site. The terms “*attB*” and “*attP*,” which refer to

attachment (or recombination) sites originally from a bacterial target and a phage donor, respectively, are used herein although recombination sites for particular enzymes may have different names. The recombination sites typically include left and right arms separated by a core or spacer region. Thus, an *attB* recombination site consists of BOB', where B and B' are the left and right arms, respectively, and O is the core region. Similarly, *attP* is POP', where P and P' are the arms and O is again the core region. Upon recombination between the *attB* and *attP* sites, and concomitant integration of a nucleic acid at the target, the recombination sites that flank the integrated DNA are referred to as "*attL*" and "*attR*." The *attL* and *attR* sites, using the terminology above, thus consist of BOP' and POB', respectively. In some representations herein, the "O" is omitted and *attB* and *attP*, for example, are designated as BB' and PP', respectively.

Description of the Preferred Embodiments

The present invention provides methods for obtaining site-specific recombination in eukaryotic cells. Unlike previously known systems for obtaining site-specific recombination, the products of the recombinations performed using the methods of the invention are stable. Thus, one can use the methods to, for example, introduce transgenes into chromosomes of eukaryotic cells and avoid the excision of the transgene that often occurs using previously known site-specific recombination systems. Stable inversions, translocations, and other rearrangements can also be obtained.

The invention employs prokaryotic recombinases, such as bacteriophage integrases, that are unidirectional in that they can catalyze recombination between two complementary recombination sites, but cannot catalyze recombination between the hybrid sites that are formed by this recombination. One such recombinase, the Φ C31 integrase, by itself catalyzes only the *attB* x *attP* reaction. The integrase cannot mediate recombination between the *attL* and *attR* sites that are formed upon recombination between *attB* and *attP*. Because recombinases such as the Φ C31 integrase cannot alone catalyze the reverse reaction, the Φ C31 *attB* x *attP* recombination is stable. This property is one that sets the methods of the present invention apart from site-specific recombination systems currently in use for eucaryotic cells, such as the Cre-*lox* or FLP-*FRT* system, where the recombination reactions can readily reverse. Use of the recombination systems of the invention provides

new opportunities for directing stable transgene and chromosome rearrangements in eukaryotic cells.

The methods involve contacting a pair of recombination sites (*e.g.*, *attB* and *attP*) that are present in a eukaryotic cell with a corresponding recombinase. The recombinase then mediates recombination between the recombination sites. Depending upon the relative locations of the two recombination sites, any one of a number of events can occur as a result of the recombination. For example, if the two recombination sites are present on different nucleic acid molecules, the recombination can result in integration of one nucleic acid molecule into a second molecule. Thus, one can obtain integration of a plasmid that contains one recombination site into a eukaryotic cell chromosome that includes the corresponding recombination site. Because the recombinases used in the methods of the invention cannot catalyze the reverse reaction, the integration is stable. Such methods are useful, for example, for obtaining stable integration into the eukaryotic chromosome of a transgene that is present on the plasmid.

The two recombination sites can also be present on the same nucleic acid molecule. In such cases, the resulting product typically depends upon the relative orientation of the sites. For example, recombination between sites that are in the direct orientation will generally result in excision of any DNA that lies between the two recombination sites. In contrast, recombination between sites that are in the reverse orientation can result in inversion of the intervening DNA. Again, the resulting rearranged nucleic acid is stable in that the recombination is irreversible in the absence of an additional factor, generally encoded by the particular bacteriophage from which the recombinase is derived, that is not normally found in eukaryotic cells. One example of an application for which this method is useful involves the placement of a promoter between the two recombination sites. If the promoter is initially in the opposite orientation relative to a coding sequence that is to be expressed by the promoter and the recombination sites that flank the promoter are in the inverted orientation, contacting the recombination sites will result in inversion of the promoter, thus placing the promoter in the correct orientation to drive expression of the coding sequence. Similarly, if the promoter is initially in the correct orientation for expression and the recombination sites are in the same orientation, contacting the

recombination sites with the promoter can result in excision of the promoter fragment, thus stopping expression of the coding sequence.

The methods of the invention are also useful for obtaining translocations of chromosomes, for example. In these embodiments, one recombination site is placed on one
5 chromosome and a second recombination site that can serve as a substrate for recombination with the first recombination site is placed on a second chromosome. Upon contacting the two recombination sites with a recombinase, recombination occurs that results in swapping of the two chromosome arms. For example, one can construct two strains of an organism, one strain of which includes the first recombination site and the second strain that contains the
10 second recombination site. The two strains are then crossed, to obtain a progeny strain that includes both of the recombination sites. Upon contacting the sites with the recombinase, chromosome arm swapping occurs.

Recombinases and Recombination Sites

The methods of the invention use recombinase systems to achieve stable
15 integration or other rearrangement of nucleic acids in eukaryotic cells. A recombinase system typically consists of three elements: two specific DNA sequences ("the recombination sites") and a specific enzyme ("the recombinase"). The recombinase catalyzes a recombination reaction between the specific recombination sites.

Recombination sites have an orientation. In other words, they are not
20 palindromes. The orientation of the recombination sites in relation to each other determines what recombination event takes place. The recombination sites may be in two different orientations: parallel (same direction) or opposite. When the recombination sites are present on a single nucleic acid molecule and are in a parallel orientation to each other, then the recombination event catalyzed by the recombinase is typically an excision of the
25 intervening nucleic acid, leaving a single recombination site. When the recombination sites are in the opposite orientation, then any intervening sequence is typically inverted.

The recombinases used in the methods of the invention can mediate site-specific recombination between a first recombination site and a second recombination site that can serve as a substrate for recombination with the first recombination site. However, in
30 the absence of an additional factor that is not normally present in eukaryotic cells, cannot

mediate recombination between two hybrid recombination sites that are formed upon recombination between the first recombination site and the second recombination site. Examples of these recombinases include, for example, the bacteriophage Φ C31 integrase (see, e.g., Thorpe & Smith (1998) *Proc. Nat'l. Acad. Sci. USA* 95: 5505-5510; Kuhstoss & Rao (1991) *J. Mol. Biol.* 222: 897-890; US Patent No. 5,190,871), a phage P4 recombinase (Ow & Ausubel (1983) *J. Bacteriol.* 155: 704-713), a *Listeria* phage recombinase, a bacteriophage R4 Sre recombinase (Matsuura *et al.* (1996) *J. Bacteriol.* 178: 3374-3376), a CisA recombinase (Sato *et al.* (1990) *J. Bacteriol.* 172: 1092-1098; Stragier *et al.* (1989) *Science* 243: 507-512), an XisF recombinase (Carrasco *et al.* (1994) *Genes Dev.* 8: 74-83), and a transposon Tn4451 TnpX recombinase (Bannam *et al.* (1995) *Mol. Microbiol.* 16: 535-551; Crelin & Rood (1997) *J. Bacteriol.* 179: 5148-5156).

Recombinase polypeptides, and nucleic acids that encode the recombinase polypeptides, are described in the art and can be obtained using routine methods. For example, a vector that includes a nucleic acid fragment that encodes the Φ C31 integrase is described in US Patent No. 5,190,871 and is available from the Northern Regional Research Laboratories, Peoria, Illinois 61604) under the accession number B-18477.

The recombinases can be introduced into the eukaryotic cells that contain the recombination sites at which recombination is desired by any suitable method. For example, one can introduce the recombinase in polypeptide form, e.g., by microinjection or other methods. In presently preferred embodiments, however, a gene that encodes the recombinase is introduced into the cells. Expression of the gene results in production of the recombinase, which then catalyzes recombination among the corresponding recombination sites. One can introduce the recombinase gene into the cell before, after, or simultaneously with, the introduction of the exogenous polynucleotide of interest. In one embodiment, the recombinase gene is present within the vector that carries the polynucleotide that is to be inserted; the recombinase gene can even be included within the polynucleotide. In other embodiments, the recombinase gene is introduced into a transgenic eukaryotic organism, e.g., a transgenic plant, animal, fungus, or the like, which is then crossed with an organism that contains the corresponding recombination sites.

Target Organisms

The methods of the invention are useful for obtaining stable integration and/or rearrangement of DNA in any type of eukaryotic cell. For example, the methods are useful for cells of animals, plants, fungi, bacteria and other microorganisms. In some
5 embodiments, the cells are part of a multicellular organism, *e.g.*, a transgenic plant or animal. The methods of the invention are particularly useful in situations where transgenic materials are difficult to obtain, such as with transgenic wheat, corn, and animals. In these situations, finding the rare single copy insertion requires the prior attainment of a large number of independently derived transgenic clones, which itself requires great expenditure
10 of effort.

Among the plant targets of particular interest are monocots, including, for example, rice, corn, wheat, rye, barley, bananas, palms, lilies, orchids, and sedges. Dicots are also suitable targets, including, for example, tobacco, apples, potatoes, beets, carrots, willows, elms, maples, roses, buttercups, petunias, phloxes, violets and sunflowers. Other
15 targets include animal and fungal cells. These lists are merely illustrative and not limiting.

Constructs for Introduction of Exogenous DNA into Target Cells

The methods of the invention often involve the introduction of exogenous DNA into target cells. For example, nucleic acids that include one or more recombination sites are often introduced into the cells. The polynucleotide constructs that are to be
20 introduced into the cells can include, in addition to the recombination site or sites, a gene or other functional sequence that will confer a desired phenotype on the cell.

In some embodiments, a polynucleotide construct that encodes a recombinase is introduced into the eukaryotic cells in addition to the recombination sites. The recombinase-encoding polypeptide can be included on the same nucleic acid as the
25 recombination site or sites, or can be introduced into the cell as a separate nucleic acid. The present invention provides nucleic acids that include recombination sites, as well as nucleic acids in which a recombinase-encoding polynucleotide sequence is operably linked to a promoter that functions in the target eukaryotic cell.

Generally, a polynucleotide that is to be expressed (*e.g.*, a recombinase-
30 encoding polynucleotide or transgene of interest) will be present in an expression cassette, meaning that the polynucleotide is operably linked to expression control signals, *e.g.*,

promoters and terminators, that are functional in the host cell of interest. The genes that encode the recombinase and the selectable marker, will also be under the control of such signals that are functional in the host cell. Control of expression is most easily achieved by selection of a promoter. The transcription terminator is not generally as critical and a variety of known elements may be used so long as they are recognized by the cell.

A promoter can be derived from a gene that is under investigation, or can be a heterologous promoter that is obtained from a different gene, or from a different species. Where direct expression of a gene in all tissues of a transgenic plant or other organism is desired, one can use a "constitutive" promoter, which is generally active under most environmental conditions and states of development or cell differentiation. Suitable constitutive promoters for use in plants include, for example, the cauliflower mosaic virus (CaMV) 35S transcription initiation region and region VI promoters, the 1'- or 2'- promoter derived from T-DNA of *Agrobacterium tumefaciens*, and other promoters active in plant cells that are known to those of skill in the art. Other suitable promoters include the full-length transcript promoter from Figwort mosaic virus, actin promoters, histone promoters, tubulin promoters, or the mannopine synthase promoter (MAS). Other constitutive plant promoters include various ubiquitin or polyubiquitin promoters derived from, *inter alia*, *Arabidopsis* (Sun and Callis, *Plant J.*, 11(5):1017-1027 (1997)), the mas, Mac or DoubleMac promoters (described in United States Patent No. 5,106,739 and by Comai *et al.*, *Plant Mol. Biol.* 15:373-381 (1990)) and other transcription initiation regions from various plant genes known to those of skill in the art. Such genes include for example, *ACT11* from *Arabidopsis* (Huang *et al.*, *Plant Mol. Biol.* 33:125-139 (1996)), *Cat3* from *Arabidopsis* (GenBank No. U43147, Zhong *et al.*, *Mol. Gen. Genet.* 251:196-203 (1996)), the gene encoding stearyl-acyl carrier protein desaturase from *Brassica napus* (Genbank No. X74782, Solocombe *et al.*, *Plant Physiol.* 104:1167-1176 (1994)), *GPc1* from maize (GenBank No. X15596, Martinez *et al.*, *J. Mol. Biol.* 208:551-565 (1989)), and *Gpc2* from maize (GenBank No. U45855, Manjunath *et al.*, *Plant Mol. Biol.* 33:97-112 (1997)). Useful promoters for plants also include those obtained from Ti- or Ri-plasmids, from plant cells, plant viruses or other hosts where the promoters are found to be functional in plants. Bacterial promoters that function in plants, and thus are suitable for use in the methods of the invention include the octopine synthetase promoter, the nopaline synthase promoter, and the manopine synthetase

promoter. Suitable endogenous plant promoters include the ribulose-1,6-biphosphate (RUBP) carboxylase small subunit (ssu) promoter, the (α -conglycinin promoter, the phaseolin promoter, the ADH promoter, and heat-shock promoters.

Promoters for use in *E. coli* include the T7, trp, or lambda promoters, a
5 ribosome binding site and preferably a transcription termination signal. For eukaryotic cells, the control sequences typically include a promoter which optionally includes an enhancer derived from immunoglobulin genes, SV40, cytomegalovirus, *etc.*, and a polyadenylation sequence, and may include splice donor and acceptor sequences. In yeast, convenient promoters include GAL1-10 (Johnson and Davies (1984) *Mol. Cell. Biol.* 4:1440-1448)
10 ADH2 (Russell *et al.* (1983) *J. Biol. Chem.* 258:2674-2682), PHO5 (*EMBO J.* (1982) 6:675-680), and MF α (Herskowitz and Oshima (1982) in *The Molecular Biology of the Yeast Saccharomyces* (eds. Strathern, Jones, and Broach) Cold Spring Harbor Lab., Cold Spring Harbor, N.Y., pp. 181-209).

Alternatively, one can use a promoter that directs expression of a gene of
15 interest in a specific tissue or is otherwise under more precise environmental or developmental control. Such promoters are referred to here as "inducible" or "repressible" promoters. Examples of environmental conditions that may effect transcription by inducible promoters include pathogen attack, anaerobic conditions, ethylene or the presence of light. Promoters under developmental control include promoters that initiate transcription only in
20 certain tissues, such as leaves, roots, fruit, seeds, or flowers. The operation of a promoter may also vary depending on its location in the genome. Thus, an inducible promoter may become fully or partially constitutive in certain locations. Inducible promoters are often used to control expression of the recombinase gene, thus allowing one to control the timing of the recombination reaction. Examples of tissue-specific plant promoters under developmental
25 control include promoters that initiate transcription only in certain tissues, such as fruit, seeds, or flowers. The tissue-specific E8 promoter from tomato is particularly useful for directing gene expression so that a desired gene product is located in fruits. *See, e.g.,* Lincoln *et al.* (1988) *Proc. Nat'l. Acad. Sci. USA* 84: 2793-2797; Deikman *et al.* (1988) *EMBO J.* 7: 3315-3320; Deikman *et al.* (1992) *Plant Physiol.* 100: 2013-2017. Other suitable promoters
30 include those from genes encoding embryonic storage proteins. Examples of environmental conditions that may affect transcription by inducible promoters include anaerobic conditions,

elevated temperature, or the presence of light. Additional organ-specific, tissue-specific and/or inducible foreign promoters are also known (*see, e.g.*, references cited in Kuhlemeier *et al* (1987) *Ann. Rev. Plant Physiol.* 38:221), including those 1,5-ribulose biphosphate carboxylase small subunit genes of *Arabidopsis thaliana* (the "ssu" promoter), which are
5 light-inducible and active only in photosynthetic tissue, anther-specific promoters (EP 344029), and seed-specific promoters of, for example, *Arabidopsis thaliana* (Krebbers *et al.* (1988) *Plant Physiol.* 87:859). Exemplary green tissue-specific promoters include the maize phosphoenol pyruvate carboxylase (PEPC) promoter, small submit ribulose bis-carboxylase promoters (ssRUBISCO) and the chlorophyll a/b binding protein promoters. The promoter
10 may also be a pith-specific promoter, such as the promoter isolated from a plant TrpA gene as described in International Publication No. W093/07278.

Inducible promoters for other organisms include, for example, the arabinose promoter, the lacZ promoter, the metallothionein promoter, and the heat shock promoter, as well as many others that are known to those of skill in the art. An example of a repressible
15 promoter useful in yeasts such as *S. pombe* is the *Pmnt* promoter, which is repressible by vitamin B1.

Typically, constructs to be introduced into these cells are prepared using recombinant expression techniques. Recombinant expression techniques involve the construction of recombinant nucleic acids and the expression of genes in transfected cells.
20 Molecular cloning techniques to achieve these ends are known in the art. A wide variety of cloning and *in vitro* amplification methods suitable for the construction of recombinant nucleic acids are well-known to persons of skill. Examples of these techniques and instructions sufficient to direct persons of skill through many cloning exercises are found in Berger and Kimmel, *Guide to Molecular Cloning Techniques, Methods in Enzymology*,
25 Volume 152, Academic Press, Inc., San Diego, CA (Berger); and Current Protocols in Molecular Biology, F.M. Ausubel *et al.*, eds., *Current Protocols*, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (1998 Supplement) (Ausubel).

The construction of polynucleotide constructs generally requires the use of
30 vectors able to replicate in bacteria. A plethora of kits are commercially available for the purification of plasmids from bacteria. For their proper use, follow the manufacturer's

instructions (see, for example, EasyPrepJ, FlexiPrepJ, both from Pharmacia Biotech; StrataCleanJ, from Stratagene; and, QIAexpress Expression System, Qiagen). The isolated and purified plasmids can then be further manipulated to produce other plasmids, used to transfect cells or incorporated into *Agrobacterium tumefaciens* to infect and transform plants. Where *Agrobacterium* is the means of transformation, shuttle vectors are constructed. Cloning in *Streptomyces* or *Bacillus* is also possible.

Selectable markers are often incorporated into the polynucleotide constructs and/or into the vectors that are used to introduce the constructs into the target cells. These markers permit the selection of colonies of cells containing the polynucleotide of interest. Often, the vector will have one selectable marker that is functional in, e.g., *E. coli*, or other cells in which the vector is replicated prior to being introduced into the target cell. Examples of selectable markers for *E. coli* include: genes specifying resistance to antibiotics, i.e., ampicillin, tetracycline, kanamycin, erythromycin, or genes conferring other types of selectable enzymatic activities such as β -galactosidase, or the lactose operon. Suitable selectable markers for use in mammalian cells include, for example, the dihydrofolate reductase gene (DHFR), the thymidine kinase gene (TK), or prokaryotic genes conferring drug resistance, gpt (xanthine-guanine phosphoribosyltransferase, which can be selected for with mycophenolic acid; neo (neomycin phosphotransferase), which can be selected for with G418, hygromycin, or puromycin; and DHFR (dihydrofolate reductase), which can be selected for with methotrexate (Mulligan & Berg (1981) *Proc. Nat'l. Acad. Sci. USA* 78: 2072; Southern & Berg (1982) *J. Mol. Appl. Genet.* 1: 327).

Selection markers for plant cells often confer resistance to a biocide or an antibiotic, such as, for example, kanamycin, G 418, bleomycin, hygromycin, or chloramphenicol, or herbicide resistance, such as resistance to chlorsulfuron or Basta. Examples of suitable coding sequences for selectable markers are: the *neo* gene which codes for the enzyme neomycin phosphotransferase which confers resistance to the antibiotic kanamycin (Beck *et al* (1982) *Gene* 19:327); the *hyg* (*hpt*) gene, which codes for the enzyme hygromycin phosphotransferase and confers resistance to the antibiotic hygromycin (Gritz and Davies (1983) *Gene* 25:179); and the *bar* gene (EP 242236) that codes for phosphinothricin acetyl transferase which confers resistance to the herbicidal compounds phosphinothricin and bialaphos.

If more than one exogenous nucleic acid is to be introduced into a target eukaryotic cell, it is generally desirable to use a different selectable marker on each exogenous nucleic acid. This allows one to simultaneously select for cells that contain both of the desired exogenous nucleic acids.

5 ***Methods for Introducing Constructs into Target Cells***

The polynucleotide constructs that include recombination sites and/or recombinase-encoding genes can be introduced into the target cells and/or organisms by any of the several means known to those of skill in the art. For instance, the DNA constructs can be introduced into plant cells, either in culture or in the organs of a plant by a variety of conventional techniques. For example, the DNA constructs can be introduced directly to
10 plant cells using biolistic methods, such as DNA particle bombardment, or the DNA construct can be introduced using techniques such as electroporation and microinjection of plant cell protoplasts. Particle-mediated transformation techniques (also known as "biolistics") are described in Klein *et al.*, *Nature*, 327:70-73 (1987); Vasil, V. *et al.*,
15 *Bio/Technol.* 11:1553-1558 (1993); and Becker, D. *et al.*, *Plant J.*, 5:299-307 (1994). These methods involve penetration of cells by small particles with the nucleic acid either within the matrix of small beads or particles, or on the surface. The biolistic PDS-1000 Gene Gun (Biorad, Hercules, CA) uses helium pressure to accelerate DNA-coated gold or tungsten microcarriers toward target cells. The process is applicable to a wide range of tissues and
20 cells from organisms, including plants, bacteria, fungi, algae, intact animal tissues, tissue culture cells, and animal embryos. One can employ electronic pulse delivery, which is essentially a mild electroporation format for live tissues in animals and patients. Zhao, *Advanced Drug Delivery Reviews* 17:257-262 (1995).

Other transformation methods are also known to those of skill in the art.
25 Microinjection techniques are known in the art and well described in the scientific and patent literature. The introduction of DNA constructs using polyethylene glycol (PEG) precipitation is described in Paszkowski *et al.*, *EMBO J.* 3:2717 (1984). Electroporation techniques are described in Fromm *et al.*, *Proc. Natl. Acad. Sci. USA*, 82:5824 (1985). PEG-mediated transformation and electroporation of plant protoplasts are also discussed in Lazzeri, P.,
30 *Methods Mol. Biol.* 49:95-106 (1995). Methods are known for introduction and expression of

- heterologous genes in both monocot and dicot plants. *See, e.g.*, US Patent Nos. 5,633,446, 5,317,096, 5,689,052, 5,159,135, and 5,679,558; Weising *et al.* (1988) *Ann. Rev. Genet.* 22:421-477. Transformation of monocots in particular can use various techniques including electroporation (*e.g.*, Shimamoto *et al.*, *Nature* (1992), 338:274-276); biolistics (*e.g.*,
 5 European Patent Application 270,356); and *Agrobacterium* (*e.g.*, Bytebier *et al.*, *Proc. Nat'l Acad. Sci. USA* (1987) 84:5345-5349).

- For transformation of plants, DNA constructs may be combined with suitable T-DNA flanking regions and introduced into a conventional *Agrobacterium tumefaciens* host vector. The virulence functions of the *A. tumefaciens* host will direct the insertion of a
 10 transgene and adjacent marker gene(s) (if present) into the plant cell DNA when the cell is infected by the bacteria. *Agrobacterium tumefaciens*-mediated transformation techniques are well described in the scientific literature. *See, for example*, Horsch *et al.* *Science*, 233:496-498 (1984), Fraley *et al.*, *Proc. Natl. Acad. Sci. USA*, 80:4803 (1983), and Hooykaas, *Plant Mol. Biol.*, 13:327-336 (1989), Bechtold *et al.*, *Comptes Rendus De L*
 15 *Academie Des Sciences Serie Iii-Sciences De La Vie-Life Sciences*, 316:1194-1199 (1993), Valvekens *et al.*, *Proc. Natl. Acad. Sci. USA*, 85:5536-5540 (1988). For a review of gene transfer methods for plant and cell cultures, *see*, Fisk *et al.*, *Scientia Horticulturae* 55:5-36 (1993) and Potrykus, *CIBA Found. Symp.* 154:198 (1990).

- Other methods for delivery of polynucleotide sequences into cells include, for
 20 example liposome-based gene delivery (Debs and Zhu (1993) WO 93/24640; Mannino and Gould-Fogerite (1988) *BioTechniques* 6(7): 682-691; Rose U.S. Pat No. 5,279,833; Brigham (1991) WO 91/06309; and Felgner *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84: 7413-7414), as well as use of viral vectors (*e.g.*, adenoviral (*see, e.g.*, Berns *et al.* (1995) *Ann. NY Acad. Sci.* 772: 95-104; Ali *et al.* (1994) *Gene Ther.* 1: 367-384; and Haddada *et al.* (1995) *Curr.*
 25 *Top. Microbiol. Immunol.* 199 (Pt 3): 297-306 for review), papillomaviral, retroviral (*see, e.g.*, Buchscher *et al.* (1992) *J. Virol.* 66(5) 2731-2739; Johann *et al.* (1992) *J. Virol.* 66 (5):1635-1640 (1992); Sommerfelt *et al.*, (1990) *Virol.* 176:58-59; Wilson *et al.* (1989) *J. Virol.* 63:2374-2378; Miller *et al.*, *J. Virol.* 65:2220-2224 (1991); Wong-Staal *et al.*, PCT/US94/05700, and Rosenberg and Fauci (1993) in *Fundamental Immunology, Third*
 30 *Edition* Paul (ed) Raven Press, Ltd., New York and the references therein, and Yu *et al.*, *Gene Therapy* (1994) *supra.*), and adeno-associated viral vectors (*see, West et al.* (1987)

Virology 160:38-47; Carter *et al.* (1989) U.S. Patent No. 4,797,368; Carter *et al.* WO 93/24641 (1993); Kotin (1994) *Human Gene Therapy* 5:793-801; Muzyczka (1994) *J. Clin. Invest.* 94:1351 and Samulski (*supra*) for an overview of AAV vectors; *see also*, Lebkowski, U.S. Pat. No. 5,173,414; Tratschin *et al.* (1985) *Mol. Cell. Biol.* 5(11):3251-3260; Tratschin *et al.* (1984) *Mol. Cell. Biol.*, 4:2072-2081; Hermonat and Muzyczka (1984) *Proc. Natl. Acad. Sci. USA*, 81:6466-6470; McLaughlin *et al.* (1988) and Samulski *et al.* (1989) *J. Virol.*, 63:03822-3828), and the like.

Methods by which one can analyze the integration pattern of the introduced exogenous DNA are well known to those of skill in the art. For example, one can extract DNA from the transformed cells, digest the DNA with one or more restriction enzymes, and hybridize to a labeled fragment of the polynucleotide construct. The inserted sequence can also be identified using the polymerase chain reaction (PCR). *See, e.g.*, Sambrook *et al.*, *Molecular Cloning - A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989 for descriptions of these and other suitable methods.

15 ***Regeneration of Transgenic Plants and Animals***

The methods of the invention are particularly useful for obtaining transgenic and chimeric multicellular organisms that have a stably integrated exogenous polynucleotide or other stable rearrangement of cellular nucleic acids. Methods for obtaining transgenic and chimeric organisms, both plants and animals, are well known to those of skill in the art.

20 Transformed plant cells, derived by any of the above transformation techniques, can be cultured to regenerate a whole plant which possesses the transformed genotype and thus the desired phenotype. Such regeneration techniques rely on manipulation of certain phytohormones in a tissue culture growth medium, typically relying on a biocide and/or herbicide marker which has been introduced together with the desired nucleotide sequences. Plant regeneration from cultured protoplasts is described in Evans *et al.*, *Protoplasts Isolation and Culture, Handbook of Plant Cell Culture*, pp. 124-176, Macmillan Publishing Company, New York (1983); and in Binding, *Regeneration of Plants, Plant Protoplasts*, pp. 21-73, CRC Press, Boca Raton, (1985). Regeneration can also be obtained from plant callus, explants, somatic embryos (Dandekar *et al.*, *J. Tissue Cult. Meth.*, 12:145 (1989); McGranahan *et al.*, *Plant Cell Rep.*, 8:512 (1990)), organs, or parts

thereof. Such regeneration techniques are described generally in Klee *et al.*, *Ann. Rev. of Plant Phys.*, 38:467-486 (1987).

The methods are useful for producing transgenic and chimeric animals of most vertebrate species. Such species include, but are not limited to, nonhuman mammals, including rodents such as mice and rats, rabbits, ovines such as sheep and goats, porcines such as pigs, and bovines such as cattle and buffalo. Methods of obtaining transgenic animals are described in, for example, Puhler, A., Ed., *Genetic Engineering of Animals*, VCH Publ., 1993; Murphy and Carter, Eds., *Transgenesis Techniques : Principles and Protocols (Methods in Molecular Biology, Vol. 18)*, 1993; and Pinkert, CA, Ed., *Transgenic Animal Technology : A Laboratory Handbook*, Academic Press, 1994. Transgenic fish having specific genetic modifications can also be made using the claimed methods. See, e.g., Iyengar *et al.* (1996) *Transgenic Res.* 5: 147-166 for general methods of making transgenic fish.

One method of obtaining a transgenic or chimeric animal having specific modifications in its genome is to contact fertilized oocytes with a vector that includes the polynucleotide of interest flanked by recombination sites. For some animals, such as mice fertilization is performed *in vivo* and fertilized ova are surgically removed. In other animals, particularly bovines, it is preferably to remove ova from live or slaughterhouse animals and fertilize the ova *in vitro*. See DeBoer *et al.*, WO 91/08216. *In vitro* fertilization permits the modifications to be introduced into substantially synchronous cells. Fertilized oocytes are then cultured *in vitro* until a pre-implantation embryo is obtained containing about 16-150 cells. The 16-32 cell stage of an embryo is described as a morula. Pre-implantation embryos containing more than 32 cells are termed blastocysts. These embryos show the development of a blastocoel cavity, typically at the 64 cell stage. If desired, the presence of a desired exogenous polynucleotide in the embryo cells can be detected by methods known to those of skill in the art. Methods for culturing fertilized oocytes to the pre-implantation stage are described by Gordon *et al.* (1984) *Methods Enzymol.* 101: 414; Hogan *et al.* *Manipulation of the Mouse Embryo: A Laboratory Manual*, C.S.H.L. N.Y. (1986) (mouse embryo); Hammer *et al.* (1985) *Nature* 315: 680 (rabbit and porcine embryos); Gandolfi *et al.* (1987) *J. Reprod. Fert.* 81: 23-28; Rexroad *et al.* (1988) *J. Anim. Sci.* 66: 947-953 (ovine embryos) and Eyestone *et al.* (1989) *J. Reprod. Fert.* 85: 715-720; Camous *et al.* (1984) *J.*

Reprod. Fert. 72: 779-785; and Heyman *et al.* (1987) *Theriogenology* 27: 5968 (bovine embryos). Sometimes pre-implantation embryos are stored frozen for a period pending implantation. Pre-implantation embryos are transferred to an appropriate female resulting in the birth of a transgenic or chimeric animal depending upon the stage of development when the transgene is integrated. Chimeric mammals can be bred to form true germline transgenic animals.

Alternatively, the methods can be used to obtain embryonic stem cells (ES) that have a single copy of the desired exogenous polynucleotide. These cells are obtained from preimplantation embryos cultured *in vitro*. See, e.g., Hooper, ML, *Embryonal Stem Cells : Introducing Planned Changes into the Animal Germline* (Modern Genetics, v. 1), Int'l. Pub. Distrib., Inc., 1993; Bradley *et al.* (1984) *Nature* 309, 255-258. Transformed ES cells are combined with blastocysts from a non-human animal. The ES cells colonize the embryo and in some embryos form the germ line of the resulting chimeric animal. See Jaenisch, *Science*, 240: 1468-1474 (1988). Alternatively, ES cells or somatic cells that can reconstitute an organism ("somatic repopulating cells") can be used as a source of nuclei for transplantation into an enucleated fertilized oocyte giving rise to a transgenic mammal. See, e.g., Wilmut *et al.* (1997) *Nature* 385: 810-813.

EXAMPLES

The following examples are offered to illustrate, but not to limit the present invention.

Example 1

The Φ C31 Recombination System Functions in *Schizosaccharomyces pombe*

This Example demonstrates that the *Streptomyces* bacteriophage Φ C31 site-specific recombination system functions in eukaryotic cells. A bacteriophage attachment site (*attP*) was introduced into a chromosome of *Schizosaccharomyces pombe* at the *S. pombe leu1* locus. This target strain was subsequently transformed with a plasmid that contains the bacterial attachment site (*attB*) linked to a *ura4⁺* selectable marker. When co-transformed with a second plasmid harboring the Φ C31 integrase gene, high efficiency transformation to *Ura⁺* was observed under conditions where the integrase gene was expressed.

Southern analysis of the integration events shows insertion of the *attB-ura4*⁺ plasmid into the *attP* site of the *leu1* locus. Nucleotide sequence of the hybrid junctions revealed that the *attB* x *attP* recombination reaction is precise.

Materials and Methods

5 ***Recombinant DNA***

Standard methods were used throughout. *E. coli* strain XL2-Blue (*recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac* [F' *proAB lacI^q ZΔM15Tn10* (Tet^r) Amy Cam^r], Strategene) served as host for DNA constructs.

Media

10 Fission yeast strains were grown on minimal medium (EMM-low glucose, from Bio101) supplemented as needed with 225 mg/l adenine, histidine, leucine or uracil. Minimal plates with 5-FOA (5-fluoroorotic acid, from Zymo Research, Inc.) were prepared according to Grimm *et al.* ((1988) *Mol. Gen. Genet.* 215: 81-86) and were supplemented with adenine, histidine, and leucine. When used, thiamine was added to 5 μg/ml.

15 ***S. pombe with ΦC31 attP target***

The 84 bp ΦC31 *attP* site (abbreviated as PP'), isolated as an *ApaI-SacI* fragment from pHS282 (Thorpe & Smith (1998) *Proc. Nat'l. Acad. Sci. USA* 95:5505-5510) was cloned into the same sites of the *S. pombe* integrating vector pJK148 (Keeney & Boeke (1994) *Genetics* 136:849-856) to make pLT44. This plasmid was targeted to the *S. pombe* *leu1-32* allele by lithium acetate mediated transformation with *NdeI* cut DNA. The recipient host FY527 (*h⁻ ade6-M216 his3-D1 leu1-32 ura4-D18*), converted to Leu⁺ by homologous recombination with pLT44, was examined by Southern analysis. One Leu⁺ transformant, designated FY527attP, was found to contain a single copy of pLT44. Another transformant, designated FY527attPx2, harbors a tandem plasmid insertion.

25 ***Integrative ura4⁺ vector with ΦC31 attB site***

The *S. pombe ura4⁺* gene, excised from pTZura4 (S. Forsburg) on a 1.8 kb *EcoRI-BamHI* fragment, was inserted into pJK148 cut with the same enzymes to create pLT40. The ΦC31 *attB* site (abbreviated as BB'), isolated from pHS21 as a 500 bp *BamHI*-

*Xba*I fragment, was ligated into pLT40 cut with those enzymes, creating pLT42. Most of the *leu1* gene was removed from pLT42 by deleting a *Xho*I fragment to create pLT45. This removed all but 229 bp of *leu1* from pLT45 and reduced its transformation efficiency to that of a plasmid without any *leu1* homology. pLT50, which has a second *attB* site in the same orientation immediately on the other side of *ura4*, was constructed by first subcloning the *attB* *Bam*HI-*Sac*I fragment from pLT42 into pUC19, excising it with *Eco*RI and *Sal*II, and subsequently inserting it into pLT45 cut with *Eco*RI and *Xho*I. The second *attB* site in the final construct was sequenced once on each strand and found to be identical to the first *attB* site.

10 **Linear DNA transformation**

The *attB-ura4⁺-attB* linear DNA was prepared as an *Att*II-*Alw*NI fragment purified from pLT50, or as a PCR product using pLT50 as template. PCR was conducted using standard conditions with a T3 primer and a second primer (5' ggc cct gaa att gtt gct tct gcc 3') corresponding to the plasmid backbone of pJK148.

15 **Repressible synthesis of Φ C31 integrase**

The *S. pombe* *Pmnt* promoter, repressible by vitamin B1, was excised as a 1.2 kb *Pst*I-*Sac*I fragment from pMO147 and inserted into the *his3⁺*, *ars1* vector pBG2 (Ohi *et al.* (1996) *Gene* 174: 315-318) cut with the same enzymes, creating pLT41. A 2.0 kb *Sac*I fragment containing the Φ C31 *int* coding region was transferred from pHS33 (Thorpe & Smith (1998) *supra.*) to the *Sac*I site of pLT41. A clone in which the *int* coding region is oriented such that expression is under the control of *Pmnt* was designated pLT43.

20 **Molecular analyses**

Southern analysis was performed using the Genius™ system from Boehringer Mannheim. A 998 bp internal *Eco*RV fragment of *leu1*, a 1.8 kb fragment of *ura4*, and the 2.0 kb Φ C31 *int* gene were digoxigen-labeled by the random primer method and used as probes. Polymerase chain reaction was performed on a Perkin Elmer Cetus Gene Amp PCR 9600 using Stratagene Turbo PFU enzyme or VENT polymerase. The standard T3 and T7 primers were used where possible. The *ura4* primer (5' gtc aaa aag ttt cgt caa tat cac 3' (SEQ ID NO: 1)) and the pJK148 primers were purchased from Operon Technologies. For

all PCR reactions an annealing temperature of 51°C and a 30-second extension time were used.

Results and Discussion

Inserting a target site into the *S. pombe* genome

5 To create a host strain with a target site for Φ C31-mediated integration, the Φ C31 attP site was inserted by homologous recombination into the *leu1* locus of the fission yeast genome to form the Leu^+ strain FY527attP (Figure 1A). Previous studies showed that when *S. pombe* DNA is cleaved with *Xba*I and probed with an internal 1 kb fragment of the *leu1*⁺ gene, the probe detects a 14 kb band (Keeney & Boeke (1994) *Genetics* 136: 849-856).
10 Insertion of the *leu*⁺ plasmid pJK148 at the *leu1*-32 locus results in detection of 3 and 18 kb bands (Figure 1A). Since pLT44 differs from pJK148 by the inclusion of an 84 bp Φ C31 attP element, integration of pLT44 at *leu1*-32 yielded the same 3 kb and 18 kb hybridization pattern in FY527attP. The absence of other hybridizing fragments indicates that the pLT44 DNA resides as a single integrated copy.

15 ***Φ C31-integrase-mediated transformation***

 FY527atttP was transformed with pLT45, which harbors *ura4*⁺ and an *attB* sequence (BB') but lacks an origin of replication. This construct was introduced by itself or with pLT43, a *his3*⁺ replicating vector that produces Φ C31 integrase. The inclusion of pLT43 increased the number of *Ura*⁺ transformants an average of 15 fold (Table 1). This
20 enhancement cannot be attributed to the recombination between pLT45 and the replication-proficient pLT43, as its effect is dependent on integrase gene expression. Transcription of the integrase gene is under the control of *Pmnt*, a promoter repressible by high levels of vitamin B1 (Maundrell, K. (1993) *Gene* 123: 127-130). The repression is not absolute (Forsburg, S. L. (1993) *Nucleic Acids Res* 21: 2955-2956) but reduces the production of
25 integrase protein. When thiamine was added to the growth medium, the number of *Ura*⁺ transformants decreased to near background level. The frequency of *Ura*⁺ transformants did not change significantly whether or not the integrase plasmid was co-selected by omission of histidine from the medium. The transformation competency of FY527atttP was estimated from the number of *His*⁺ transformants obtained with pLT43 or its progenitor plasmid pBG2.

Compared to the frequency of either replicating plasmid, the pLT43-dependent transformation of FY527attP averaged about 15%.

Table 1: Integrase-dependent site-specific insertion in *S. pombe* FY527attP.

5

DNA (1 µg)	Selection	B1 (5 µg)	Transformants per 10 ⁷ cells (±sd) *	Relative Value [§]	Class a	Class b	Others
pLT43	His ⁺	-	7200 (±2200)	100			
pLT45	Ura ⁺	-	63 (±10)	1	0% [†]	0% [†]	100% [‡]
pLT45 + pLT43	Ura ⁺	-	1100 (±120)	15	88% [†]	6% [†]	6% [†]
pLT45 + pLT43	Ura ⁺	+	120 (±16)	2	0% [†]	25% [†]	75% [‡]

*From three independent experiments

[§](transformation efficiency of the DNA of interest)/(transformation efficiency of pLT43) x 100

10 [†] n=16

[‡] n=8

ΦC31-integrase promoted attP x attB recombination

Recombination between the pLT45-encoded ΦC31 *attB* element and the chromosomally situated attP sequence would incorporate the circular DNA into the *leu1* locus as depicted in Figure 1B. If this reaction occurs, *Xba*I-fractionated genomic DNA from the Ura⁺ transformants is probed with *leu1* DNA, the 3 kb band will remain unchanged, while the 18 kb band will increase to ~23 kb (Figure 1C). Randomly selected Ura⁺ colonies were examined by hybridization analysis. Of eight isolates derived from experiments where ΦC31 integrase gene expression was derepressed by the omission of thiamine, seven showed the presence of this ~23 kb band. This same size band hybridized to the *ura4* probe. This contrasts with the lack of *ura4* hybridization with the parental strain, as expected from its *ura4*-D18 deletion allele. One of these seven isolates showed additional bands hybridizing to both probes. This candidate appears to have a DNA rearrangement at the *leu1* locus in

20

addition to a site-specific recombination event. The *leu1* rearrangement was probably catalyzed by the operative *S. pombe* homologous recombination system. The remaining isolate had not experienced a site-specific recombination event and appeared to have gained uracil prototrophy by recombination between pLT45 and pLT43. Of these eight isolates, half were selected as both Ura⁺ and His⁺, but no significant difference was found between this group and the group selected for Ura⁺ only.

From transformation experiments plated in the presence of vitamin B1, an equal number of Ura⁺ transformants was examined by DNA hybridization. The thiamine-repressible *Pnmt* promoter is expected to limit integrase production, and thereby site-specific integration. Two of the eight Ura⁺ candidates isolated from this low frequency transformation showed a band of 23 kb hybridizing to *leu1* and to the *ura4* probe. However, since both probes detected an additional band, they do not represent correct integration events, and we grouped them as class b integrants. In the other six isolates, the hybridization patterns are difficult to interpret. In some of them, the 3 kb band was not detected by the *leu1* probe, as though the locus has experienced some rearrangement. In many of them, the weak hybridization to *ura4* suggests that the Ura⁺ phenotype may not be due to the stable maintenance of pLT45 in the genome.

To ascertain the proportion of transformants maintaining the integrase plasmid in the absence of selection, the blots were re-probed with the integrase gene sequence. Those selected as Ura⁺ His⁺ would be expected to maintain the plasmid, and did so, as the hybridization revealed. Five of the eight isolates selected as Ura⁺ without regard to the His phenotype also gave bands hybridizing to the integrase probe. To confirm that loss of *int* would not affect stable integration, another set of randomly chosen Ura⁺ cells were grown non-selectively for a number of generations and screened for His⁺ progeny that have lost pLT43. The analysis of eight representative Ura⁺ His⁺ clones showed that all had a single copy of pLT45 precisely integrated at the chromosome-situated *attP* site. The DNA of these integrants did not hybridize with the integrase probe. In contrast, the background frequency Ura⁺ clones derived by transformation of pLT45 alone gave the parental configuration of hybridizing bands at the *leu1* locus and additional faint bands at 5 kb and 7 kb. These observations are consistent with either integration of pLT45 elsewhere in the

genome, or maintenance of the plasmid in some cells despite the lack of a *S. pombe* replication origin.

Conservative site-specific recombination

PCR was used to retrieve the *attP/attB* recombinant junctions from three
5 representative *Ura*⁺ candidates. One of the hybrid sites, *attR* (PB') would be flanked by T3
and T7 promoters; the other site, *attL* (BP') by the T3 promoter and *ura4* DNA (Figure 1C).
In each case, primer pairs directed to these sequences amplified a band of the expected size
while the original *attP* (PP') was no longer found. This contrasts with the parental strain
FY527attP, where *attP*, but neither *attL* nor *attR*, was detected. The nucleotide sequence of
10 three representative *attL* and *attR* PCR products showed the absence of accompanying
mutations. Hence, as in bacteria and mammalian cells, Φ C31 mediated site-specific
recombination in *S. pombe* is a conservative recombination reaction.

Φ C31 integrase does not excise integrated molecules

Thorpe and Smith ((1998) *Proc. Natl. Acad. Sci. USA* 95: 5505-5510) did not
15 detect reversal of the Φ C31 integrase reaction by analysis of gel-fractionated DNA
fragments. We examined the possibility of a reverse reaction through a genetic selection
strategy. The precise integration of pLT45 into FY527attP was confirmed for three clones
by Southern analysis; these strains were then re-transformed with pLT43. Excision of
pLT45 would result in loss of the *ura4*⁺ marker; the *Ura*⁻ phenotype can be scored on plates
20 with 5-FOA (Grimm *et al.* (1988) *Mol. Gen. Genet.* 215: 81-86). The frequencies of *Ura*⁻
segregants from cultures of the three *Ura*⁺ His⁻ progenitors were 5.7×10^{-4} , 7.1×10^{-4} and 5.6
 $\times 10^{-4}$. In contrast, the frequencies of *Ura*⁻ colonies from the three *Ura*⁺ His⁺ derivatives were
somewhat higher: 1.1×10^{-2} , 3.8×10^{-3} and 2.3×10^{-3} , respective 19-, 5- and 4-fold increases.
When a control vector lacking the integrase gene, pBG2, was used instead, increased rates
25 of 5-FOA resistance were also found: 1.0×10^{-2} , 1.0×10^{-2} , and 8.0×10^{-3} , respectively. The
transformation process itself appears mutagenic.

Three *Ura*⁻ His⁺ clones from each of the three cultures that had been
transformed by pLT45 were analyzed by Southern blotting. One isolate had a DNA pattern
consistent with stable integration of pLT45 into FY527attP. Therefore, in this clone, the
30 *Ura*⁻ phenotype was caused by a mutation that did not appreciably alter the restriction

pattern, rather than by reversal of the site-specific recombination reaction. The second clone showed a Southern pattern characteristic of FY527attP lacking a pLT45 insertion, the third had a pattern consistent with a mixture of two types of cells, those like FY527attP without a pLT45 insertion, and those like the FY527attP progenitor strain FY527. The latter structure
5 could arise from intrachromosomal homologous recombination between the *leu* repeats, reversing the insertion of pLT44 (Figure 1A). If precise excision of the integrated plasmid DNA occurred in the latter two candidates, the attP site would be regenerated; this would be detectable with PCR. The size of the PCR product was that expected for an intact hybrid site, the presence of the hybrid site was confirmed by sequencing the PCR product. These
10 observations are consistent with the idea that deletion of the *ura4* gene occurred by some mechanism other than Φ C31-mediated excision.

Summary

The integration of a circular molecule at a single target site was an efficient process yielding precise insertions in nearly all transformants. The few aberrant events we
15 observed are probably largely attributable to the *S. pombe* recombination system acting on the *leu1* repetitive DNA. When integrase production was limited through the repression of its promoter, the number of transformants was reduced to near background level. Under these conditions, few of the recovered transformants were derived from Φ C31 site-specific recombination. Functional operation of the Φ C31 site-specific recombination system in
20 eukaryotic cells presents new opportunities for the manipulation of transgenes and chromosomes. The Φ C31 system can be used with selective placement of *attB* and *attP* sites to delete, invert or insert DNA. An important feature of this system is that the *attB* x *attP* reaction is irreversible in the absence of an excision-specific protein.

Example 2

25 The Φ C31 Integrase Functions in CHO Cells to Create Stable Integration

This Example describes an experiment in which the Φ C31 integrase was tested for ability to mediate recombination between *attB* and *attP* recombination sites in Chinese hamster ovary (CHO) cells.

Methods

The CHO cell line 51YT211 was transfected with the *attP*-containing plasmid pFY1, which included a selectable marker that confers zeocin resistance (Figure 2). After being single colony purified twice, six zeocin resistant cell lines were isolated. Analysis by
5 Southern DNA hybridization confirmed that each of the six cell lines had at least one molecule of pFY1 integrated into the genome.

Each of the six cell lines was transfected with the *attB*-containing plasmid pFY9 and the *int*-containing plasmid pFY6 to test for site-specific recombination between the *attB* sites on pFY9 and the *attP* site on the chromosomal copy of pFY1. As control, the
10 same cell lines were transfected with pFY9, but without the *int*-containing pFY6. The pFY9 plasmid included a neomycin resistance selectable marker under the control of an SV40 early promoter, as well as a green fluorescent protein (GFP) coding sequence that is not linked to a promoter. Site-specific recombination would thus be expected to place the GFP coding sequence under the control of a human cytomegalovirus promoter that was included
15 in pFY1, resulting in expression of GFP.

Results

Transfection results: Neomycin resistant colonies were placed under the microscope to observe whether the *GFP* gene is active. A large percentage of the cells transfected with pFY9+pFY6, but only a few of the cells transfected with the pFY9 alone
20 showed GFP activity. This is consistent with site-specific integration of pFY9 when co-transfected with pFY6, and random insertion of pFY9 in the absence of a co-transfected *int* gene.

PCR analysis was conducted using a primer set that corresponds to *Pc* (human cytomegalovirus promoter) and *GFP* (Figure 2). These primers would be expected
25 to amplify a band of ~0.6 kb corresponding to the integration junction. As neomycin resistant colonies could arise from both site-specific integration and random integration, and that the GFP marker does not confer a selectable trait, it was difficult to obtain pure cultures of integrant clones. Therefore, pools of neomycin resistant cells from each transfected line were subjected to PCR analysis to examine if the integration junction were present among
30 the neomycin resistant cells. A band of the expected size of ~0.6 kb was obtained from two

lines. This indicates that the *attB* x *attP* recombination junction has formed linking *Pc* with *GFP*.

Example 3

ΦC31 Integrase Catalyzes Site-Specific Recombination in CHO Cells

- 5 This Example describes a second experiment in which the ΦC31 integrase was tested for ability to integrate a DNA molecule into the chromosome of Chinese hamster ovary (CHO) cells through the recombination between *attP* and *attB* sites.

Methods

Plasmid constructs

- 10 Chromosomal *attB* target constructs pFY12, pFY14 and pFY15

The plasmid pcDNA3.1/His/lacZ (Invitrogen) was used as a vector backbone. A synthetic oligonucleotide contained different length of the *attB* site, flanked by *HindIII* and *KpnI* sites, was inserted between the *HindIII* (AAGCTT) and *KpnI* (GGTACC) sites of pcDNA3.1/His/lacZ.

- 15 The plasmid pFY12 contains 90 bp of the *attB* sequence (AAGCTT gacggctctcg aagccgcggt gcgggtgccca gggcgtgccc ttgggtctccc cgggcgcgta ctccacctca cccatctggt ccatcatgat GGTACC) (SEQ ID NO: 2).

The plasmid pFY14 contained 50 bp of the *attB* site (AAGCTT gcgggtgccca gggcgtgccc ttgggtctccc cgggcgcgta ctccacctca TGGTACC) (SEQ ID NO: 3).

- 20 The plasmid pFY15 contained 30 bp of *attB* (AAGCTT ccagggcgtg cccttgggct ccccgggcgc ATGGTACC) (SEQ ID NO: 4).

Integrating *attP* plasmids pFY17, pFY19, pFY20

- 25 The *hpt* gene encoding for resistance to hygromycin, obtained as a 1.6 kb *BamHI* to *KpnI* fragment from pED113, was inserted between the *BamHI* and *KpnI* sites of pBluescript II SK to generate the control plasmid pBSK-hpt.

A synthetic oligonucleotide containing different lengths of the *attP* site was inserted between *SacI* (GTCGAC) and *BamHI* (GGATCC) sites in pBSK-hpt to generate the following plasmids:

a) The plasmid pFY17 contains 90 bp (GAGCTC-gaagcgggtt tcgggagtag-tgccccaaact ggggtaacct ttgagttctc tcagttgggg gcgtagggtc gccgacatga cacaaggggt-GGATCC) of *attP* site (SEQ ID NO: 5).

b) The plasmid pFY19 contains 50 bp of *attP* site (GAGCTC-tgccccaaact ggggtaacct ttgagttctc tcagttgggg gcgtagggtc-GGATCC) (SEQ ID NO: 6).

c) The plasmid pFY20 contains 32 bp of *attP* site (GAGCTC-actggggtaa cctttgagtt ctctcagttg ggATCC) (SEQ ID NO: 7) is called pFY20.

Integrase expressing construct pFY6

An *EcoRI* to *BamHI* fragment containing the nearly complete open reading frame of the integrase gene was inserted between the *EcoRI* and *BamHI* sites of pcDNA3.1/Zeo(-) (Invitrogen). A synthetic oligonucleotide (GGGCCCCGCCACGATGACA CAAGGGGTTGTGACCGGGGTGGACACGTACGCGGGTGCTTACGACCGTCAGTCG CGCGAGCGCGAGAATTC) (SEQ ID NO: 8) containing a Kozack sequence and the N-terminal amino acid coding sequences of the integrase gene was subsequently inserted between the *ApaI* and *EcoRI* sites to reconstruct the open reading frame. This orientation places a complete integrase coding region under the control of the CMV (human cytomegalovirus) promoter in pcDNA3.1/Zeo(-).

Transfection protocol

The CHO cell line K-1 was transfected with *attB* target constructs pFY12, pFY14 or pFY15 (Figure 3). These plasmids harbor the selectable marker for neomycin resistance, and an *attB* site of various lengths located between *Pc* (human cytomegalovirus promoter) and the *lacZ* coding region. Plasmids pFY12, pFY14 and pFY15 contain, respectively, 90, 50 and 30 bp of the *attB* sequence. Neomycin-resistant cell lines were obtained from consecutive purification of single colonies. Four lines of each construct were used for integration experiments.

Each of the 12 lines was transfected with pFY6, a Φ C31 integrase expression plasmid, along with an integration vector, pFY17, pFY19, or pFY20. The plasmids pFY17, pFY19 and pFY20 harbor an *attP* sequence of lengths 90, 50 and 32 bp, respectively. The *attP* sequence is situated upstream of the *hpt* open reading frame, which encodes hygromycin phosphotransferase, an enzyme that confers resistance to hygromycin. There is

no promoter upstream of the *attP*-*hpt* segment and *hpt* is therefore not expressed unless the plasmid integrates into the genome in such a way that the *hpt* coding region fuses with a genomic promoter. For control, pBSK-*hpt* was used to monitor the frequency of promoter fusion to *hpt*. The plasmid pBSK-*hpt* is identical to pFY17, pFY19, and pFY20 except it
5 lacks an *attP* sequence. The recombination between *attP* and *attB* sites is expected to insert the integration vector into the chromosome target to generate a *Pc-attL-hpt* linkage. Expression of *hpt* will confer resistance to hygromycin.

Results

Transfection results: Hygromycin resistant colonies were scored for each
10 integration plasmid which was transfected into the 12 cell lines (Table 2). From 1×10^6 cells plated, pBSK-*hpt* transfections failed to produce a significant number of resistant colonies. This indicates that the frequency of the *hpt* coding region fusing to a genomic promoter is extremely low. In contrast, pFY17, pFY19 and pFY20 yielded up to a thousand fold higher number of hygromycin resistant colonies, depending on the particular integration plasmid
15 and the particular cell line. Higher numbers of hygromycin resistant colonies were produced from the transfection of pFY19 or pFY17 into FY12 lines. This indicates that the recombination between longer *attB* and *attP* sequences is more efficient than the recombination between shorter *attB* and *attP* sites.

PCR was used to detect the expected ~0.8 Kb junction band from
20 representative colonies. Primers corresponding to the human cytomegalovirus promoter and the *hpt* coding region amplified a PCR product of the expected size (0.8 kb). This indicates that *Pc* is linked to the *hpt* coding region, consistent with recombination between the genomic *attB* site and the plasmid *attP* sequence.

Example 4

25 The Φ C31 Integrase Functions in Plant Chromosomes to Recombine *attP* and *attB* Sites

This example describes an experiment in which the Φ C31 integrase was tested for ability to recombine *attP* and *attB* sites that are present in a plant chromosome. The constructs and strategy for this experiment are shown in Figure 4.

Table 2
Number of hygromycin resistant colonies per 1×10^6 transfected cells.

Target cell lines	Integration plasmids			
	pFY17 (90 bp AttP)	pFY19 (50 bp AttP)	pFY20 (32 bp AttP)	pBSK-hpt (no attP site)
(attB-90)				
FY12-1	256	856	275	0
FY12-2	976	896	185	0
FY12-3	246	976	114	2
FY12-4	964	896	327	0
(attB-50)				
FY14-3	23	240	45	0
FY14-7	96	245	67	0
FY14-8	21	135	49	2
FY14-9	89	255	78	1
(attB-30)				
FY15-1	0	24	0	0
FY15-2	0	345	34	0
FY15-3	55	455	23	1
FY15-4	0	0	0	0

5

Methods

The construct pWP29 contains the fragment consisting of *35S-attP-npt-attB-gus*, flanked by RB and LB, where *35S* is the cauliflower mosaic virus promoter, *npt* is the coding region for neomycin phosphotransferase, and *gus* is the coding region for glucuronidase. RB and LB are the right and left *Agrobacterium* T-DNA border sequences, respectively. The *attP* site between *35S* and *npt* serves as a non-translated leader sequence. Transcription of *npt* by *35S* confers resistance to kanamycin. The *gus* coding region is not transcribed due to the lack of an upstream promoter.

A second construct used for plant transformation is pWP24. This construct contains the fragment *Pnos-npt-35S-int*, flanked by RB and LB, where *Pnos* is the nopaline synthase promoter, and *int* is the Φ C31 integrase coding region. Both *npt* and *int* are transcribed from their respective upstream promoters.

If the two constructs were present in the same genome, the expression of *int* from the pWP24 bearing chromosome would be expected to produce functional Φ C31 integrase to catalyze the recombination between *attB* and *attP* sites situated on the pWP29-bearing chromosome. The recombination event would be expected to delete the *npt* gene from the pWP29 construct and fuse *35S* to *gus*. The resulting configuration would be *35S-attR-gus*, where *attR* is a hybrid site formed by the recombination between *attP* and *attB*, also designated as PB' (Figure 4). The deletion of *npt* brings *gus* under the transcription of *35S* and would be expected to yield plants with GUS enzyme activity. This activity can be detected through histochemical staining of the plant tissue.

10 Results

A transient expression assay was conducted to determine whether pWP29 was functional for recombination. Through the biolistics-mediated delivery of naked DNA, pWP29 was cointroduced with pWP8 into maize BMS cells. The construct pWP8 has the integrase gene fused behind the maize ubiquitin promoter for expression in monocot cells. Blue spots were observed when both plasmids were co-introduced, but were not found if only one of the plasmids was used. This indicated that site-specific recombination took place in maize cells and that the *attP* and *attB* sites in pWP29 were functional sites.

Kanamycin resistant tobacco plants were regenerated by Agrobacterium-mediated transformation using pWP29 or pWP24. Another transient expression assay was conducted to determine whether the pWP24 lines produced functional integrase. The construct pWP29 was introduced into the pWP24 plants through biolistics mediated delivery of naked DNA. Cells that take up the pWP29 DNA would be expected to express GUS enzyme activity as a result of the formation of a *35S-attR-gus* configuration. Indeed, two lines, 24.3 and 24.4 yielded blue spots consistent of functional integrase-mediated site-specific recombination between the *attP* and *attB* sites.

These two pWP24 integrase lines were crossed to pWP29 tester lines to produce progeny with the chromosomes carrying pWP29 and pWP24 in the same genome. Table 3 summarizes the results from the genetic crosses between integrase (24.3, 24.4) and tester lines (29.2, 29.4, 29.5, 29.19). In each case, representative progeny seedlings were germinated in the absence of selection and histochemically stained for GUS enzyme activity.

The table lists the number of progeny that stained blue. As the primary transformed pWP24 and pWP29 lines are hemizygous for their respective transgene, only a quarter of the progeny would be expected to carry both transgene types. The sample sizes were small, so an apparent deviation from the expected frequency is not unusual.

5

Table 3: Progeny that showed *gus* expression from histochemical staining.

Male Donor plant line	Female Recipient plant line	Number of progeny stained for <i>gus</i> activity	Number of progeny that show <i>gus</i> activity.	% positive for <i>gus</i> activity
24.3+	29.2	38	11	29%
29.2	24.3+	38	1	2.6%
29.4	24.3+	18	3	16%
24.3+	29.5	38	4	10%
29.5	24.3+	26	0	0
24.4	29.2	38	7	19%
29.2	24.4+	38	7	19%
29.4	24.4+	19	8	42%
24.4+	29.5	38	17	45%
29.5	24.4+	20	6	30%
29.19	24.4+	18	7	39%

The intensity of staining varied depending on the combination of lines used as parental lines. Those with progeny with a greater proportion of the tissue staining blue indicate that the recombination event was more efficient. Conversely, those yielding progeny with less uniform staining indicate that the recombination event was less efficient. This variation among the different progeny pools is probably due to effects caused by the position of integration of the transgenes. Of the two integrase lines, 24.4 appears more efficient in promoting site-specific recombination. This is probably due to a higher level of *int* gene expression. Staining patterns produced by crossing 24.4 to 29.4 and 29.19 are consistent with

10

15

the experimental design that *int* promoted site-specific recombination of *attB* and *attP* results in the activation of *gus* gene activity.

Example 5

ΦC31 Integrase Catalyzes Integration of a Circular Plasmid into a Plant Chromosome

5 This example describes an experiment in which the ΦC31 integrase was tested for ability to insert a circular plasmid molecule into the plant chromosome through *attP* x *attB* site-specific recombination. This experiment is diagrammed in Figure 5.

Methods

10 The target construct pWP6 contains the fragment consisting of *35S-attP-npt*, flanked by RB and LB. The *attP* site between *35S* and *npt* serves as a non-translated leader sequence. Transcription of *npt* by *35S* confers resistance to kanamycin.

 The integrating construct pYJC43 has the fragment *attB-hpt*, where *hpt* codes for resistance to hygromycin. The integrase expression construct is pYJC41, in which *35S* transcribes *int*.

15 The target construct pWP6 was placed into a plant chromosome through random integration of pWP6 DNA. Kanamycin resistant plants harboring a single copy of the pWP6 transgene are then subsequently transformed with pYJC43 and pYJC41. The transient expression of *int* from pYJC41 was expected to catalyze the recombination between the *attB* site of pYJC43 and the chromosomally-situated *attP* site of the pWP6 transgene. The specific recombination between *attB* and *attP* sites would insert the pYJC43
20 circular molecule into the chromosome to generate a *35S-attL-hpt* linkage. Note that because the *attP* and *attB* sites are depicted in the inverted orientation, the *attL* site will likewise be in an inverted orientation, or designated P'B, the same as BP' in the drawn in an inverted orientation. A functional *35S-attL-hpt* linkage would confer a hygromycin
25 resistance phenotype.

Results

 Kanamycin resistant tobacco plants harboring pWP6 were obtained through *Agrobacterium*-mediated transformation. Southern hybridization analysis detected one line that harbors a single copy of the pWP6 transgene. Progeny from this line, WP6.1, were

germinated aseptically and protoplasts were made from these plants. The protoplasts were transformed by the combination of pYJC43 and pYJC41 DNA by the polyethylene glycol method for direct DNA transformation. The protoplasts were then imbedded into agarose and cultured to form calli in the presence of hygromycin. The rate of callus formation in the
5 absence of hygromycin selection was 4×10^{-4} . This is about 10 fold lower than usual, but is within the range of variability observed in protoplast transformation experiments. In the presence of hygromycin selection, the rate of callus formation was 7×10^{-5} . This indicates that about 18% of the calli that regenerated from protoplasts contained the integration vector at the target site. When the integrase construct pYJC41 was excluded from the
10 transformation, the rate of callus formation was $<1 \times 10^{-5}$. The higher frequency of hygromycin resistant calli produced by inclusion of the integrase expressing plasmid pYJC41 is consistent with the integrase promoted site-specific integration of pYJC43 into the chromosomal *attP* target.

15 It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference for all purposes.

WHAT IS CLAIMED IS:

1 1. A eukaryotic cell that comprises a prokaryotic recombinase polypeptide
2 or a nucleic acid that encodes a prokaryotic recombinase, wherein the recombinase can
3 mediate site-specific recombination between a first recombination site and a second
4 recombination site that can serve as a substrate for recombination with the first
5 recombination site, but in the absence of an additional factor that is not present in the
6 eukaryotic cell cannot mediate recombination between two hybrid recombinase
7 recombination sites that are formed upon recombination between the first recombination site
8 and the second recombination site.

1 2. The eukaryotic cell of claim 1, wherein the recombinase is selected
2 from the group consisting of a bacteriophage Φ C31 integrase, a coliphage P4 recombinase, a
3 Listeria phage recombinase, a bacteriophage R4 Sre recombinase, a CisA recombinase, an
4 XisF recombinase, and a transposon Tn4451 TnpX recombinase.

1 3. The eukaryotic cell of claim 1, wherein the recombinase is a
2 bacteriophage Φ C31 integrase.

1 4. The eukaryotic cell of claim 1, wherein the first recombination site is an
2 *attB* site and the second recombination site is an *attP* site.

1 5. The eukaryotic cell of claim 1, wherein the cell further comprises a first
2 recombinase recombination site.

1 6. The eukaryotic cell of claim 1, wherein the cell comprises a nucleic acid
2 that comprises a coding sequence for an recombinase polypeptide, which coding sequence is
3 operably linked to a promoter that mediates expression of the recombinase-encoding
4 polynucleotide in the eukaryotic cell.

1 7. The eukaryotic cell of claim 6, wherein the nucleic acid further
2 comprises a selectable marker.

1 8. The eukaryotic cell of claim 6, wherein the promoter is an inducible or a
2 repressible promoter.

1 9. The eukaryotic cell of claim 8, wherein the nucleic acid is the plasmid
2 pLT43.

1 10. The eukaryotic cell of claim 1, wherein the eukaryotic cell is selected
2 from the group consisting of an animal cell, a plant cell, a yeast cell, an insect cell and a
3 fungal cell.

1 11. The eukaryotic cell of claim 10, wherein the eukaryotic cell is a
2 mammalian cell.

1 12. The eukaryotic cell of claim 10, wherein the eukaryotic cell is present in
2 a multicellular organism.

1 13. A method for obtaining site-specific recombination in a eukaryotic cell,
2 the method comprising:

3 providing a eukaryotic cell that comprises a first recombination site and
4 a second recombination site, which second recombination site can serve as a substrate for
5 recombination with the first recombination site;

6 contacting the first and the second recombination sites with a
7 prokaryotic recombinase polypeptide, resulting in recombination between the recombination
8 sites, thereby forming one or two hybrid recombination sites;

9 wherein the recombinase polypeptide can mediate site-specific
10 recombination between the first and second recombination sites, but cannot mediate
11 recombination between two hybrid recombination sites in the absence of an additional factor
12 that is not present in the eukaryotic cell.

1 14. The method of claim 13, wherein the eukaryotic cell is selected from the
2 group consisting of a yeast cell, a fungal cell, a plant cell, an insect cell and an animal cell.

1 15. The method of claim 13, wherein the first recombination site is present
2 in a chromosome of the eukaryotic cell.

1 16. The method of claim 15, wherein the second recombination site is
2 present in a second chromosome of the eukaryotic cell and contacting the first and second
3 recombination sites with the recombinase results in translocation of chromosome arms.

1 17. The method of claim 13, wherein the first recombination site and the
2 second recombination site are present on a single nucleic acid molecule.

1 18. The method of claim 17, wherein the first recombination site and the
2 second recombination site are in a direct orientation.

1 19. The method of claim 18, wherein the recombination results in excision
2 of the portion of the nucleic acid molecule that lies between the first and second
3 recombination sites.

1 20. The method of claim 17, wherein the first recombination site and the
2 second recombination site are in an inverted orientation.

1 21. The method of claim 20, wherein the recombination results in inversion
2 of the portion of the nucleic acid molecule that lies between the first and second
3 recombination sites.

1 22. The method of claim 13, wherein the eukaryotic cell comprises a
2 polynucleotide that encodes the recombinase polypeptide.

1 23. The method of claim 22, wherein the recombinase-encoding
2 polynucleotide is operably linked to a promoter which mediates expression of the
3 polynucleotide in the eukaryotic cell.

1 24. The method of claim 23, wherein the promoter is an inducible or a
2 repressible promoter.

1 25. The method of claim 24, wherein the promoter is a *Pmmt* promoter.

1 26. A method for obtaining a eukaryotic cell having a stably integrated
2 transgene, the method comprising:
3 introducing a nucleic acid into a eukaryotic cell that comprises a first
4 recombination site, wherein the nucleic acid comprises a transgene and a second
5 recombination site which can serve as a substrate for recombination with the first
6 recombination site; and
7 contacting the first and the second recombination sites with a
8 prokaryotic recombinase polypeptide, wherein the recombinase polypeptide catalyzes
9 recombination between the first and second recombination sites, resulting in integration of
10 the nucleic acid at the first recombination site, thereby forming a hybrid recombination site
11 at each end of the nucleic acid;
12 wherein the recombinase polypeptide can mediate site-specific
13 recombination between the first and second recombination sites, but cannot mediate
14 recombination between two hybrid recombination sites in the absence of an additional factor
15 that is not present in the eukaryotic cell.

1 27. The method of claim 26, wherein the recombinase polypeptide is
2 selected from the group consisting of a bacteriophage Φ C31 integrase, a coliphage P4
3 recombinase, a Listeria phage recombinase, a bacteriophage R4 Sre recombinase, a CisA
4 recombinase, an XisF recombinase, and a transposon Tn4451 TnpX recombinase.

1 28. The method of claim 27, wherein the recombinase is a Φ C31 integrase.

1 29. The method of claim 26, wherein the recombinase polypeptide is
2 introduced into the eukaryotic cell by expression of a polynucleotide that encodes the
3 recombinase polypeptide.

1 30. The method of claim 29, wherein the polynucleotide that encodes the
2 recombinase polypeptide is operably linked to a promoter that functions in the eukaryotic
3 cell.

1 31. The method of claim 30, wherein the promoter is an inducible or a
2 repressible promoter.

1 32. A nucleic acid that comprises a polynucleotide sequence that encodes a
2 bacterial recombinase polypeptide operably linked to a promoter that functions in a
3 eukaryotic cell, wherein the recombinase polypeptide cannot mediate recombination between
4 two hybrid recombination sites that are formed upon recombination between a first
5 recombination site and a second recombination site in the absence of an additional factor.

1 33. The nucleic acid of claim 32, wherein the nucleic acid further comprises
2 at least one recombination site that is recognized by the recombinase polypeptide.

1 34. The nucleic acid of claim 32, wherein the nucleic acid comprises a
2 plasmid vector.

1 35. The nucleic acid of claim 34, wherein the vector is pLT43.

1 36. A eukaryotic cell that comprises a polynucleotide that comprises a first
2 bacteriophage Φ C31 recombination site.

1 37. The eukaryotic cell of claim 36, wherein the recombination site is
2 selected from the group consisting of *attP* and *attB*.

1 38. The eukaryotic cell of claim 36, wherein the eukaryotic cell further
2 comprises a second polynucleotide that comprises a second Φ C31 recombination site that
3 undergoes recombination with the first Φ C31 recombination site when contacted with a
4 Φ C31 integrase polypeptide.

1 39. The eukaryotic cell of claim 38, wherein:
2 the first recombination site is *attB* and the second recombination site is
3 *attP*; or
4 the first recombination site is *attP* and the second recombination site is
5 *attB*.

1 40. The eukaryotic cell of claim 38, wherein the second polynucleotide
2 further comprises a transgene.

1 41. The eukaryotic cell of claim 38, wherein the second polynucleotide
2 further comprises a selectable marker.

1 42. The eukaryotic cell of claim 36, wherein the eukaryotic cell further
2 comprises a Φ C31 integrase polypeptide.

1 43. The eukaryotic cell of claim 36, wherein the eukaryotic cell further
2 comprises a nucleic acid that comprises a polynucleotide that encodes a Φ C31 integrase
3 polypeptide.

1 44. The eukaryotic cell of claim 43, wherein the nucleic acid further
2 comprises a selectable marker.

1 45. The eukaryotic cell of claim 43, wherein the nucleic acid further
2 comprises a promoter which results in expression of the Φ C31 integrase-encoding
3 polynucleotide in the cell.

1 46. The eukaryotic cell of claim 45, wherein the promoter is an inducible
2 promoter.

1 47. The eukaryotic cell of claim 36, wherein the eukaryotic cell is selected
2 from the group consisting of a yeast cell, a fungal cell, a plant cell, and an animal cell.

Figure 1






Figure 2**Transgene Integration in CHO Cell Line****Site Specific Expression of GFP**

Figure 3

Transgene Integration in CHO Cell Line

Hygromycin Resistance from attB x attP recombination



Pc = human cytomegalovirus promoter

Ps = SV40 early promoter

zeo = zeomycin resistance coding region

neo = neomycin resistance coding region

hpt = hygromycin resistance coding region

lacZ = beta galactosidase coding region

PP' = attP**BB'** = attB**PB'** = attR**BP'** = attL

Figure 4

Excision of DNA from Tobacco Genome





Figure 5

Integration of DNA into the tobacco genome



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



INTERNATIONAL BUREAU OF PATENT COOPERATION
3, rue de la Harpe, CHATELAIN
1205 Yverdon, SUISSE

(43) International Publication Date
1 February 2001 (01.02.2001)


PCT

(10) International Publication Number
WO 01/07572 A3

- (51) International Patent Classification⁷: C12N 5/10, 15/79, 15/90 // 9/22
- (21) International Application Number: PCT/US00/19983
- (22) International Filing Date: 21 July 2000 (21.07.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/145,469 23 July 1999 (23.07.1999) US
- (71) Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; Office Of Technology Transfer, 1111 Franklin Street, 12th floor, Oakland, CA 94607-5200 (US). THE UNITED STATES OF AMERICA as represented by the SECRETARY OF AGRICULTURE [US/US]; 1400 Independence Avenue S.W., Washington, DC 20250 (US).
- (72) Inventors: OW, David, W.; 127 Brenner Street, Hercules, CA 94547-3749 (US). CALENDAR, Richard; 940 Euclid Street, Berkeley, CA 94708-1436 (US). THOMASON, Lynn; 1061 H. Monroe Street #7, Albany, CA 94706-2282 (US).
- (74) Agents: SMITH, Timothy, L. et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th floor, San Francisco, CA 94111-3834 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

[Continued on next page]

(54) Title: DNA RECOMBINATION IN EUKARYOTIC CELLS BY THE BACTERIOPHAGE PHIC31 RECOMBINATION SYSTEM



(57) Abstract: This invention provides methods for obtaining specific and stable integration of nucleic acids into eukaryotic cells. The invention makes use of site-specific recombination systems that use prokaryotic recombinase polypeptides, such as the Φ C31 integrase, that can mediate recombination between the recombination sites, but not between hybrid recombination sites that are formed upon the recombination. Thus, the recombination is irreversible in the absence of additional factors. Eukaryotic cells that contain the recombinase polypeptides, or genes that encode the recombinases, are also provided.

WO 01/07572 A3

(88) Date of publication of the international search report:
19 April 2001

Published:

— *With international search report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

Inten of Application No

PCT/US 00/19983

A. CLASSIFICATION F SUBJECT MATTER
 IPC 7 C12N5/10 C12N15/79 C12N15/90 //C12N9/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 00 11155 A (UNIV LELAND STANFORD JUNIOR) 2 March 2000 (2000-03-02) page 4 page 5, line 25 -page 6, line 2	1-8, 10-47
A	THORPE, H. M. ET AL.: "In vitro site-specific integration of bacteriophage DNA catalyzed by a recombinase of the resolvase/invertase family" PNAS, vol. 95, 1998, pages 5505-5510, XP002157128 cited in the application abstract	1-47



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

S document member of the same patent family

Date of the actual completion of the international search

12 January 2001

Date of mailing of the international search report

29/01/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Mata Vicente, T.

INTERNATIONAL SEARCH REPORT

Intern
al Application No
PCT/US 00/19983

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 18222 A (ALONSO JUAN C ; ROJO FERNANDO (ES); BERNARD ANTONIO (ES); DIAZ VICE) 15 April 1999 (1999-04-15) page 14, paragraph 2 -----	1-47

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern # Application No

PCT/US 00/19983

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0011155	A	02-03-2000	AU 5898599 A	14-03-2000
WO 9918222	A	15-04-1999	AU 9466898 A	27-04-1999
			EP 1021550 A	26-07-2000